Clinical trial
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00015834 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00015834 |
|---|---|
| Title | STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia |
| Official title | A Phase I/II Trial of STI571 and High-Dose Cytarabine in Myeloid Blast Crisis of Chronic Myeloid Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Relapsing Chronic Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | imatinib mesylate, cytarabine |
| Enrollment | 46 |
| Start date | May 1, 2001 |
| Primary completion | Apr 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: